Here

Avian (Bird) Flu: Is There a Role for Rapid Tests?

With human infections of bird flu (avian influenza) reported in Asia and Eastern Europe, public health officials have moved swiftly to develop policies on surveillance, diagnosis, and treatment. The virus in question is the H5N1 subtype of influenza A, which has become epidemic...

Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema

NEW YORK, May 31, 2007 /PRNewswire-FirstCall/ -- LevPharmaceuticals, Inc. ("Lev" or the "Company") announced today thatit has completed patient treatment in the prophylactic portion ofits Phase III clinical trial of C1-esterase inhibitor (C1-INH) forhereditary angioedema (HAE). The clinical trial, designated CHANGE,examined and evaluated the efficacy and safety of C1-INHreplacement thera...

Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial

WASHINGTON, May 22, 2007 /PRNewswire/ -- Results from analyseslooking at factors contributing to successful treatment ofulcerative colitis (UC), were presented at Digestive Disease Week(DDW) this week. Both of these studies were funded by Procter &Gamble (P&G) Pharmaceuticals, Inc. Findings from one studyoffer new information on improvement of quality of life for UCpatients t...

DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - Dyax Corp.(Nasdaq:DYAX) announced today positive topline results from itsPhase 3, placebo-controlled trial, EDEMA3, for its lead productcandidate DX-88 (ecallantide), for hereditary angioedema (HAE). Awebcast presentation of the EDEMA3 data is scheduled for Tuesday,April 17, 2007 at 12:30 p.m. ET. DX-88, an internally discovered, recombina...

Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY

- Study shows orally-delivered GLP-1 is able to stimulate insulinrelease TARRYTOWN, N.Y., March 29, 2007 /PRNewswire-FirstCall/ --Emisphere Technologies, Inc. reported today results of two clinicalstudies conducted in collaboration with Professor ChristophBeglinger, M.D. Division of Gastroenterology and Hepatology,University Hospital Basel in Basel, Switzerland. The objective ofthe study...

Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema

Company anticipates second quarter BLA filing for C1-inhibitorreplacement therapy NEW YORK, March 14, 2007 /PRNewswire-FirstCall/ -- LevPharmaceuticals, Inc. (Lev) today announced positive results fromits pivotal U.S. Phase III trial of C1-esterase inhibitor (C1-INH)for the acute treatment of hereditary angioedema (HAE). In theacute study, which is part of the company's CHANGE trials(C1-...

Data From Adherex's European Phase Ib/II Trial of ADH-1 to be Presented at International Symposium on Targeted Anticancer Therapies

RESEARCH TRIANGLE PARK, N.C., Mar 8, 2007 (CCNMatthews via COMTEXNews Network) -- Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), abiopharmaceutical company with a broad portfolio of oncologyproducts under development, today announced that Dr. AntonellaPerotti, MD, Istituto Nazionale dei Tumori Milano, SENDOFoundation, an investigator in Adherex's European Phase Ib/II studyof single-agent AD...